Review Article: Improving Mitochondrial Function: Current Therapeutic Perspectives in Neurodegenerative Diseases (Paper July 2026)

Key Takeaways

• Mitochondrial dysfunction identified as early driver in AD and PD
• Lifestyle measures like exercise and ketogenic diet show preventive benefits
• Emerging therapies include mitophagy enhancers, USP30 inhibitors, and mtDNA editing
• Sex-specific mitochondrial support suggests estrogen loss may heighten AD risk

Pulse Analysis

Mitochondrial health has moved to the forefront of neurodegenerative research, with growing evidence that energy deficits, reactive oxygen species, and disrupted dynamics precede hallmark protein aggregates in Alzheimer’s and Parkinson’s disease. By framing mitochondria as a network hub rather than a downstream casualty, the review underscores how early bioenergetic failure can amplify amyloid‑β toxicity, tau phosphorylation, and α‑synuclein accumulation, creating a vicious cycle that accelerates neuronal loss. This perspective reshapes drug discovery pipelines, urging scientists to prioritize upstream correction before irreversible damage sets in.

The therapeutic landscape outlined in the paper spans low‑tech lifestyle interventions—regular aerobic exercise, ketogenic and Mediterranean‑style diets rich in polyphenols—to high‑tech modalities such as mitophagy activators, USP30 inhibitors, and even mitochondrial DNA editing. While exercise and dietary shifts have robust epidemiologic support and favorable safety profiles, advanced approaches grapple with delivery challenges, off‑target effects, and regulatory uncertainty. The authors note that many promising compounds demonstrate protection only in pre‑symptomatic animal models, highlighting a translational gap that biotech investors must assess when allocating capital toward mitochondrial‑focused pipelines.

Looking ahead, the review calls for precise mitochondrial biomarkers and patient stratification, especially considering sex‑specific differences like post‑menopausal estrogen decline that may heighten Alzheimer’s susceptibility. Early‑stage clinical trials that integrate metabolic imaging, circulating mtDNA metrics, and genotype‑guided enrollment could accelerate proof‑of‑concept for both lifestyle and molecular therapies. Until such data emerge, mitochondrial targeting remains a compelling yet cautious avenue—one that could redefine preventive neurology if delivery, safety, and efficacy hurdles are systematically overcome.